X-Vax Technology, Inc., a Jupiter, Fla.-based biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, raised $56m in an upsized Series A financing.
– Johnson & Johnson Innovation – JJDC, Inc. (JJDC);
– Adjuvant Capital;
– Serum Institute;
– Alexandria Venture Investments; and
– FF DSF VI, a scout investment vehicle out of Founders Fund.
The company intends to use the funds to advance its lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.
Led by Ulf Wiinberg, President and Chief Executive Officer, X-Vax Technology is a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. The company has created a herpes vaccine candidate called ∆gD-2 (delta gD-2), which is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, X-Vax has been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.